What is Gyre Therapeutics, Inc.'s stock issuance proceeds?

Gyre Therapeutics, Inc. (GYRE) reported stock issuance proceeds of $21K in Q1 2026.

How has Gyre Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?

Gyre Therapeutics, Inc.'s stock issuance proceeds decreased by 95.9% year-over-year, from $509K to $21K.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Gyre Therapeutics, Inc. GYRE Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Viking TherapeuticsVKTX

$450K+28.9%

Theravance BiopharmaTBPH

$241K+1,105%

Rigel PharmaceuticalsRIGL

$321K-33.7%

Zevra Therapeutics, Inc.ZVRA

$752K—

LQD

Liquidia CorporationLQDA

$1.75M+38.6%

Madrigal Pharmaceuticals, Inc.MDGL

——

Other financials

Income statement

See full

Revenue$22.5M+2.1%

Gross profit$21.3M+0.6%

Operating income-$9.4M-512%

Net income-$8.7M-422%

EPS (diluted)-$0.10—

Balance sheet

See full

Cash & equivalents$37.5M+149%

Total debt$823.0K-48.1%

Total equity$101.3M+48.7%

Total assets$162.0M+24.8%

Cash flow

See full

Operating cash flow$3.2M+2,565%

CapEx$178.0K+45.9%

Free cash flow$3.0M+1,296%

Valuation

See full

Market cap$694.58M-4.7%

Enterprise value$657.9M-8.0%

P/S5.9×-1.3×

Profitability

See full

Gross margin95.1%-1.1pp

Operating margin-0.1%-10.4pp

Net margin6.3%+3.3pp

FCF margin2.6%—

Returns & leverage

See full

Return on equity8.2%+4.2pp

Debt / equity0×0.0×

Current ratio4.6×+1.0×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s stock issuance proceeds?: Gyre Therapeutics, Inc. (GYRE) reported stock issuance proceeds of $21K in Q1 2026.
How has Gyre Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?: Gyre Therapeutics, Inc.'s stock issuance proceeds decreased by 95.9% year-over-year, from $509K to $21K.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.